Please try another search
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies. The company is headquartered in Agoura Hills, California.
Name | Age | Since | Title |
---|---|---|---|
Vuong Trieu | 58 | 2014 | Chairman & CEO |
John H. Sampson | - | - | Member of Medical Advisory Board |
Reinhard Wilhelm von Roemeling | - | - | Member of Medical Advisory Board |
Anatoly Dritschilo | 77 | - | Member of Medical Advisory Board |
Stuart E. Siegel | - | - | Member of Medical Advisory Board |
Steven W. King | 59 | 2020 | Consultant & Director |
Anthony E. Maida | 72 | 2020 | Chief Medical Officer – Translation Medicine & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review